



Alliance Medical Limited is pleased to announce the expansion of its UK radiopharmacy division, (Alliance Medical Radiopharmacy) with the opening of its latest fully licenced production unit in Dinnington, South Yorkshire. The site, which was originally opened in 2005 by IBA Molecular UK and subsequently ceased operation in 2010, was acquired by AML in 2013 with a view to recommissioning it initially for the manufacture of PET radioisotopes to support a national increase in demand for molecular imaging.

Refurbishment and recommissioning of the facility commenced in February 2017, with the building upgraded and extended to accommodate two medical cyclotrons (an existing 18MeV IBA Cyclone 18/9 and a new 24MeV ACSI TR24) - particle accelerators used in medical imaging for the production of short-lived radionuclides - and associated manufacturing facilities, plant room and offices.

The facility in Dinnington, Alliance Medical Radiopharmacy's fifth manufacturing site in the UK, will not only provide additional capacity and access to FDG and other PET tracers, but in a UK first, will have the future capability of producing a safe and reliable supply of cyclotron-produced Technetium-99m (Tc-99m) which is used in over 80% of all nuclear medicine imaging procedures and which currently relies on non-UK, reactor-based production. This will further support molecular imaging departments around the country and support NHS Trusts to deliver rapid access to diagnostics in areas such as oncology, cardiology and neurology.

Commercial manufacture of FDG will commence on Monday 25 Jan 2021 and will supplement the four established Alliance Medical Radiopharmacy sites, based in Preston, Keele, Guildford and Sutton.

Richard Evans, UK Managing Director, commented "I am delighted that after a huge amount of hard work we can announce the opening of the Dinnington Radiopharmacy production unit. Thanks to all of the AML Radiopharmacy team both at Dinnington and across the country for their hard work and dedication to get this unit open. The additional capacity now available will benefit thousands of NHS patients across the country and help them get diagnostic treatment quickly and efficiently. Thanks also to the MHRA for their help in working with us and also to NHSE Special Commissioners for their continued support.

Dinnington will dramatically increase AML's capacity to produce PET tracers and help produce new and improved tracers to benefit cancer patients across the country."

David Cahill, Chief Commercial and Strategy Officer, commented "The vision, right from acquiring this site in 2013, was always to reinstate this as a world class manufacturing facility. Not only are we expanding access to PET tracers here in the UK for both diagnostic and research purposes, but we will also have the future capability to support the wider Nuclear Medicine community via access to and availability of Tc-99m."

About Alliance Medical

Alliance Medical provides medical imaging and support services to more than 500,000 patients in the UK each year, employing over 1,000 people in a UK network of static and mobile scanning units and radiopharmaceutical production units. We also operate across Europe in Germany, Ireland, Italy, the Netherlands, and Spain. We work collaboratively with clinicians, health care organisations and academic institutions to provide high quality and cost-effective imaging and support services. We operate flexible, innovative models that places patients, clinicians and Trusts at the heart of what we do. We have a proven track record of service delivery across both the publicly and privately funded healthcare markets in the UK and Europe with an emphasis on the quality and sustainability of services we provide.

Learn more about the work we do:
www.alliancemedical.co.uk

- ▶ **PET (Positron Emission Tomography)** is a functional imaging technique that uses radioactive substances known as radiotracers to visualise and measure changes in metabolic processes.
- ▶ **FDG (fludeoxyglucose F-18)** is a radiopharmaceutical used in the medical imaging modality Positron Emission Tomography.

